See today's BioWorld Asia
To read the full story, subscribe or sign in.

Ausperbio bags $73M series B for hep B-targeting RNA therapy

Dec. 31, 2024
By Marian (YoonJee) Chu
Ausperbio Therapeutics Inc. raised $110 million from two financing rounds in 2024 to advance its lead antisense oligonucleotide candidate as a functional cure for chronic hepatitis B.
BioWorld Asia Financings American Association for the Study of Liver Diseases Infection Antisense Series B Asia-Pacific China U.S. NMPA